Hikma Pharmaceuticals Signs Licensing Agreement To Supply Enoxaparin

LONDON (Alliance News) - FTSE 250-listed Hikma Pharmaceuticals PLC on Tuesday said it signed a ...

Alliance News 24 April, 2018 | 9:38AM
Email Form

LONDON (Alliance News) - FTSE 250-listed Hikma Pharmaceuticals PLC on Tuesday said it signed a licensing contract with Laboratorios Farmaceuticos Rovi SA for its vein thrombosis treatment medication enoxaparin sodium.

Hikma said Rovi's enoxaparin sodium is an anticoagulant medication, which is used to treat and prevent deep vein thrombosis and pulmonary embolism. It is a biosimilar of Sanofi-Aventis's Lovenox and Clexane. Last month, the Spanish pharmaceutical company achieved national authorisation for its biosimilar of enoxaparin in 16 European markets.

Under the terms of the agreement, Hikma said it has the exclusive rights to distribute and market enoxaparin across its Middle East and North Africa markets, exluding Morocco.

"We are very pleased to be expanding our partnership with Rovi, adding this important cardiovascular product to our product portfolio in the Middle East and North Africa region," said Mazen Darwazah, chief executive & chairman of Middle East, North Africa and emerging markets.

"This partnership demonstrates the successful execution of our strategy to grow our biosimilar portfolio and improve patients' access to high-quality, affordable medicines," Darwazah added.

Shares in Hikma were trading 1.2% higher at 1,242.50 pence per share early on Tuesday.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Hikma Pharmaceuticals PLC 2,562.00 GBX 1.87

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites